Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

: ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria - JSON Representation

Raw json | Download

{
  "resourceType" : "Group",
  "id" : "279340",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2025-03-15T20:58:52.894Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
    ]
  },
  "text" : {
    "status" : "empty",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail" : {
        "name" : "Brian S. Alper"
      }
    },
    {
      "url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as",
      "valueMarkdown" : "ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-11-16. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340#json."
    }
  ],
  "url" : "https://fevir.net/resources/Group/279340",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "urn:ietf:rfc:3986",
      "value" : "https://fevir.net/FOI/279340",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "title" : "ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description" : "Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria\na. T1DM-specific criteria\n..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have been on the following daily insulin therapy for at least 1 year\n...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or\n...2) continuous subcutaneous insulin infusion (CSII)\n..iii. are between 18 and 64 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening\nb. T2DM-specific criteria\n..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\n..iii. are between 20 and 70 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening",
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "membership" : "conceptual",
  "combinationMethod" : "any-of",
  "characteristic" : [
    {
      "code" : {
        "text" : "Defined by Reference"
      },
      "valueReference" : {
        🔗 "reference" : "Group/279347",
        "type" : "Group",
        "display" : "CohortDefinition: T1DM-specific criteria"
      },
      "exclude" : false,
      "description" : "T1DM-specific criteria\ni. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\nii. have been on the following daily insulin therapy for at least 1 year\n..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)\niii. are between 18 and 64 years old at the time of informed consent\niv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening"
    },
    {
      "code" : {
        "text" : "Defined by Reference"
      },
      "valueReference" : {
        🔗 "reference" : "Group/279346",
        "type" : "Group",
        "display" : "CohortDefinition: T2DM-specific criteria"
      },
      "exclude" : false,
      "description" : "T2DM-specific criteria\ni. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening"
    }
  ]
}